Guan Yun, Li Jing, Gong Xiu, Zhu Huaguang, Li Chao, Mei Guanghai, Liu Xiaoxia, Pan Li, Dai Jiazhong, Wang Yang, Wang Enmin, Liu Ying, Wang Xin
CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Fudan University, 12 Wulumuqi Road (M), Shanghai 200040, China.
Neurosurgical Institute, Fudan University, 12 Wulumuqi Road (M), Shanghai 200040, China.
Brain Sci. 2022 Apr 2;12(4):471. doi: 10.3390/brainsci12040471.
(1) Background: Hypofractionated stereotactic radiotherapy (HSRT) and anti-vascular endothelial growth factor (VEGF) antibodies have been reported to have a promising survival benefit in recent studies. Anlotinib is a new oral VEGF receptor inhibitor. This report describes our experience using HSRT and anlotinib for recurrent glioblastoma (rGBM). (2) Methods: Between December 2019 and June 2020, rGBM patients were retrospectively analysed. Anlotinib was prescribed at 12 mg daily during HSRT. Adjuvant anlotinib was administered d1-14 every 3 weeks. The primary endpoint was the objective response rate (ORR). Secondary endpoints included overall survival (OS), progression-free survival (PFS) after salvage treatment, and toxicity. (3) Results: Five patients were enrolled. The prescribed dose was 25.0 Gy in 5 fractions. The median number of cycles of anlotinib was 21 (14-33). The ORR was 100%. Three (60%) patients had the best outcome of a partial response (PR), and 2 (40%) achieved a complete response (CR). One patient died of tumour progression at the last follow-up. Two patients had grade 2 hand-foot syndrome. (4) Conclusions: Salvage HSRT combined with anlotinib showed a favourable outcome and acceptable toxicity for rGBM. A prospective phase II study (NCT04197492) is ongoing to further investigate the regimen.
(1) 背景：近期研究报道，短程立体定向放射治疗（HSRT）和抗血管内皮生长因子（VEGF）抗体具有显著的生存获益。安罗替尼是一种新型口服VEGF受体抑制剂。本报告介绍了我们使用HSRT和安罗替尼治疗复发性胶质母细胞瘤（rGBM）的经验。(2) 方法：回顾性分析2019年12月至2020年6月期间的rGBM患者。HSRT期间安罗替尼的给药剂量为每日12 mg。辅助性安罗替尼每3周第1 - 14天给药。主要终点为客观缓解率（ORR）。次要终点包括总生存期（OS）、挽救治疗后的无进展生存期（PFS）和毒性。(3) 结果：纳入5例患者。处方剂量为25.0 Gy分5次。安罗替尼的中位疗程数为21（14 - 33）。ORR为100%。3例（60%）患者获得部分缓解（PR）的最佳疗效，2例（40%）达到完全缓解（CR）。1例患者在最后一次随访时死于肿瘤进展。2例患者出现2级手足综合征。(4) 结论：挽救性HSRT联合安罗替尼对rGBM显示出良好的疗效和可接受的毒性。一项前瞻性II期研究（NCT04197492）正在进行，以进一步研究该方案。
